Our CEO, Hanadie Yousef, discussed Juvena’s growing and advancing pipeline of tissue restorative biologics for myopathies and obesity with Miranda Schmalfuhs from Pharmaceutical Executive
Our Senior Director of Discovery and Platform, Dr. Thach Mai, attended Google Cloud Next ‘25 to explore cutting-edge AI and cloud innovations transforming drug discovery and precision therapeutics
Juvena was honored to present at the IGF and Insulin System in Physiology and Disease Gordon Research Conference! Our CSO and Co-Founder, Jeremy O’Connell, had a great opportunity to present our JUV-161 program and engage in insightful discussions on the latest advancements in IGF biology
Our SVP of Drug Development, Dr. Banmeet Anand, presented Juvena’s clinical stage metabolic program (JUV-161) that enhances muscle regeneration for the treatment of sarcopenia and myotonic dystrophy type 1 (DM1) at the International Conference of Frailty and Sarcopenia in Toulouse, France
Our CEO Dr. Hanadie Yousef presented updates on Juvena’s platform and advancing pipeline of tissue restorative biologics for muscle and metabolic diseases at Biocom California’s Global Life Science Partnering and Investor Conference
Hanadie Yousef, Juvena’s CEO and co-founder, participated in #BiotechCEOSisterhood, #Breaking7%, and PINK Tuesday events, connecting with leaders and allies to drive innovation and collaboration
Dr. Hanadie Yousef, CEO and co-founder of Juvena, and Dr. Austin Wang, Corporate Development Manager, hosted an executive roundtable on weight loss for longevity at the #WuXiGlobalForum, fostering engaging discussions with industry leaders
Juvena’s CEO and co-founder, Dr. Hanadie Yousef, shared insights on “Enhancing Longevity: Delaying the Diseases That Age Us” at the #BiotechShowcase panel and highlighted Juvena’s progress, including the upcoming clinical trials for JUV-161
As a Tech Pioneer company, CEO Hanadie Yousef participated in the third Annual Meeting of the Innovator Communities at the World Economic Forum’s New York office, amongst over 80 Founders and CEOs
